市場調査レポート

商品コード

1401866

ムスカリン性アセチルコリン受容体の2030年までの世界市場予測：タイプ別、製品別、流通チャネル別、用途別、エンドユーザー別、地域別分析

Muscarinic Acetylcholine Receptor Market Forecasts to 2030 - Global Analysis By Type (M1, M4, M5 and Other Types), Product (Tropicamide, Nu-0467154, Anauex-273 and Other Products), Distribution Channel, Application, End User and By Geography

出版日: 2023年12月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,150 601,376円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 760,777円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 920,178円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,086,825円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.91円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、世界のムスカリン性アセチルコリン受容体市場は2023年に17億5,000万米ドルを占め、予測期間中にCAGR 6.9％で成長し、2030年には27億9,000万米ドルに達すると予測されています。

ムスカリン性アセチルコリン受容体は、シナプス後ニューロンを抑制することができる受容体のクラスであり、いくつかの末梢と中枢活動の制御に関与しています。副交感神経系の生理的帰結を調節する役割を担っています。抑制作用と興奮作用の両方があり、反応を遮断したり刺激したりすることができ、コリン作動性ニューロンとしてアセチルコリン産生ニューロンに貯蔵されます。

医学研究を支援する米国の非営利団体である米国心臓協会によると、米国におけるアルツハイマー病と関連する認知症の罹患者数は、2060年までに930万人に増加すると予想されています。

神経疾患の有病率の増加

アルツハイマー病、パーキンソン病、統合失調症などの神経疾患は、人口の高齢化やライフスタイルの変化により、より広まりつつあります。ムスカリン性アセチルコリン受容体はこれらの疾患において重要な役割を担っており、医薬品開発の魅力的な対象となっています。さらに、医療システムにおける神経疾患の負担に対処する切実な必要性と、革新的な治療法に対するニーズの高まりから、市場は拡大しています。このことは、この分野の製薬会社や調査研究者にとって大きな可能性をもたらすと同時に、患者にとっても希望となる可能性を秘めています。

副作用と安全性の懸念

ムスカリン性アセチルコリン受容体を標的とする薬剤は、口渇、目のかすみ、便秘、めまい、認知障害などの副作用を引き起こす可能性があります。これらの副作用は患者のコンプライアンスやQOLに影響を及ぼす可能性があり、特に加齢に関連した問題により既にこれらの症状を経験している可能性のある高齢者集団においてはなおさらです。治療効果と副作用のバランスをとることは難しく、患者のアドヒアランスを制限する可能性があります。また、心血管系や呼吸器系に影響を及ぼす可能性があるため、安全性にも懸念が生じる。そのため、市場拡大の足かせとなっています。

標的療法

標的療法は、より正確な治療選択肢を提供し、副作用を最小限に抑え、治療成果を高めることができます。個々の患者の受容体プロファイルに合わせた介入を行うことで、個別化医療が現実のものとなり、アルツハイマー病、統合失調症、パーキンソン病などの治療に革命をもたらす可能性があります。さらに、ドラッグデリバリーシステムや診断ツールの進歩は、こうした治療の効果を最適化することができます。このことは、製薬会社や研究者が革新的で患者中心のソリューションを開発し、市場の成長を促進するための有望な道を示しています。

規制上のハードル

ムスカリン受容体を標的とする薬剤の開発には、大規模な臨床試験や安全性評価など、厳格な規制要件を遵守する必要があります。このような要求は、開発期間の延長、コストの増加、規制当局による頓挫のリスクをもたらします。遅延や却下は市場参入の妨げとなり、製薬会社の足かせとなります。こうした障害はイノベーションを阻害し、神経疾患や精神疾患に対する新たな治療法の提供を遅らせ、市場の成長と競合に影響を与える可能性があります。

COVID-19の影響

COVID-19の流行は筋アセチルコリン受容体市場に大きな影響を与えています。サプライチェーンの中断、研究開発業務の制限、医療資源の再編成などの結果、臨床試験や医薬品開発が遅れています。さらに、ムスカリン受容体関連医薬品への患者のアクセスは、テレヘルスの重視と対面での医療受診の減少によって影響を受けた。しかし、パンデミックは神経学的研究と技術革新の重要性を浮き彫りにし、医療制度が将来の課題と機会に適応するにつれて、この市場への関心と投資が高まる可能性もあります。

予測期間中はトロピカミド分野が最大になる見込み

トロピカミド分野が最大のシェアを占めると推定されます。トロピカミドは、抗コリン薬またはムスカリン拮抗薬として知られる薬剤クラスに属する医薬品です。眼科領域では、主にサイクロプレン作動薬や散瞳薬として使用されています。トロピカミドは、虹彩と毛様体筋のムスカリン性アセチルコリン受容体を阻害することにより、眼球のピント調節筋を麻痺させ、瞳孔を拡大させます。トロピカミドの眼科領域への応用は、精神疾患や神経疾患を含む様々な疾患を治療するためにこれらの受容体を対象とする薬や治療法を含む、より大きな市場とのつながりを強調するものです。

精神疾患分野は予測期間中に最も高いCAGRが見込まれる

精神疾患分野は、予測期間中に有利な成長を遂げると予測されています。ムスカリン性アセチルコリン受容体は、中枢神経系に存在する受容体の一群で、さまざまな脳機能の調節に重要な役割を果たしています。これらの受容体の機能不全は、統合失調症、双極性障害、大うつ病性障害など、いくつかの精神疾患に関与しています。同市場では、精神疾患を患う人々により効果的で的を絞った治療を提供できる革新的な治療法に焦点が当てられており、医療の進歩にとって有望な手段となっています。そのため、この分野の需要が高まると思われます。

最大のシェアを占める地域

アジア太平洋は、医療支出の増加と高齢者人口の増加により、予測期間中に最大の市場シェアを獲得しました。この市場には、神経系に不可欠な成分であるムスカリン性アセチルコリン受容体に関連する医薬品、調査ツール、診断薬が含まれます。この市場は、神経疾患の流行、医薬品開発の進展、神経学研究の増加といった要因の影響を受けています。さらに、この地域の大手製薬会社、研究機関、バイオテクノロジー企業は、これらの受容体に関連する製品の開発と商業化に取り組んでいます。学術界と産業界の共同研究は一般的であり、精密医療へのアプローチと標的治療は、この地域における個別化医療ソリューションへの注目の高まりを反映した主要動向です。

CAGRが最も高い地域：

北米は、確立された医療インフラの存在、研究開発投資の高さ、患者数の多さから、予測期間中に有益な成長を遂げることが予想されます。市場規模は、これらの受容体に関連する疾患の流行、医薬品開発の進歩、神経学と関連分野の研究といった要因に影響されます。さらに、製薬会社はアルツハイマー病などの神経疾患を含む様々な病状に対して、ムスカリン性アセチルコリン受容体を標的とした薬剤を開発しています。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます。

企業プロファイル
- 追加市場参入企業の包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推定・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

イントロダクション
北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他の欧州
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他のアジア太平洋
南米
- アルゼンチン
- ブラジル
- チリ
- その他の南米
中東とアフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他の中東とアフリカ

第11章主要発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品の発売
事業拡大
その他の主要戦略

第12章企業プロファイル

AstraZeneca
Anavex Life Sciences Corp.
Sosei Heptares.
Karuna Therapeutics.
Sumitomo Dainippon Pharma Co., Ltd.
NeuroHealing Pharmaceuticals Inc.
Heptares Therapeutics Ltd.
Pfizer Inc.
GlaxoSmithKline plc
Novartis AG
Johnson & Johnson
Boehringer Ingelheim International Gmbh
Eli Lilly and Company
Takeda Pharmaceutical Company Ltd
Merck & Co., Inc
AbbVie Inc.
Elsevier B.V.
Eurofins DiscoverX Corporation
Novus Biologicals

図表

List of Tables

Table 1 Global Muscarinic Acetylcholine Receptor Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Muscarinic Acetylcholine Receptor Market Outlook, By Type (2021-2030) ($MN)
Table 3 Global Muscarinic Acetylcholine Receptor Market Outlook, By M1 (2021-2030) ($MN)
Table 4 Global Muscarinic Acetylcholine Receptor Market Outlook, By M4 (2021-2030) ($MN)
Table 5 Global Muscarinic Acetylcholine Receptor Market Outlook, By M5 (2021-2030) ($MN)
Table 6 Global Muscarinic Acetylcholine Receptor Market Outlook, By Other Types (2021-2030) ($MN)
Table 7 Global Muscarinic Acetylcholine Receptor Market Outlook, By Product (2021-2030) ($MN)
Table 8 Global Muscarinic Acetylcholine Receptor Market Outlook, By Tropicamide (2021-2030) ($MN)
Table 9 Global Muscarinic Acetylcholine Receptor Market Outlook, By Nu-0467154 (2021-2030) ($MN)
Table 10 Global Muscarinic Acetylcholine Receptor Market Outlook, By Anauex-273 (2021-2030) ($MN)
Table 11 Global Muscarinic Acetylcholine Receptor Market Outlook, By Other Products (2021-2030) ($MN)
Table 12 Global Muscarinic Acetylcholine Receptor Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 13 Global Muscarinic Acetylcholine Receptor Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 14 Global Muscarinic Acetylcholine Receptor Market Outlook, By Speciality Stores (2021-2030) ($MN)
Table 15 Global Muscarinic Acetylcholine Receptor Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 16 Global Muscarinic Acetylcholine Receptor Market Outlook, By Application (2021-2030) ($MN)
Table 17 Global Muscarinic Acetylcholine Receptor Market Outlook, By Chronic Obstructive Pulmonary Disease (2021-2030) ($MN)
Table 18 Global Muscarinic Acetylcholine Receptor Market Outlook, By Alzeheimers Disease (2021-2030) ($MN)
Table 19 Global Muscarinic Acetylcholine Receptor Market Outlook, By Psychiatric Disorders (2021-2030) ($MN)
Table 20 Global Muscarinic Acetylcholine Receptor Market Outlook, By Attention Deficit Hyperactivity Disorder (2021-2030) ($MN)
Table 21 Global Muscarinic Acetylcholine Receptor Market Outlook, By Memory Impairment (2021-2030) ($MN)
Table 22 Global Muscarinic Acetylcholine Receptor Market Outlook, By End User (2021-2030) ($MN)
Table 23 Global Muscarinic Acetylcholine Receptor Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
Table 24 Global Muscarinic Acetylcholine Receptor Market Outlook, By Healthcare Facilities (2021-2030) ($MN)
Table 25 Global Muscarinic Acetylcholine Receptor Market Outlook, By Research Institutes (2021-2030) ($MN)
Table 26 Global Muscarinic Acetylcholine Receptor Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
Table 27 North America Muscarinic Acetylcholine Receptor Market Outlook, By Country (2021-2030) ($MN)
Table 28 North America Muscarinic Acetylcholine Receptor Market Outlook, By Type (2021-2030) ($MN)
Table 29 North America Muscarinic Acetylcholine Receptor Market Outlook, By M1 (2021-2030) ($MN)
Table 30 North America Muscarinic Acetylcholine Receptor Market Outlook, By M4 (2021-2030) ($MN)
Table 31 North America Muscarinic Acetylcholine Receptor Market Outlook, By M5 (2021-2030) ($MN)
Table 32 North America Muscarinic Acetylcholine Receptor Market Outlook, By Other Types (2021-2030) ($MN)
Table 33 North America Muscarinic Acetylcholine Receptor Market Outlook, By Product (2021-2030) ($MN)
Table 34 North America Muscarinic Acetylcholine Receptor Market Outlook, By Tropicamide (2021-2030) ($MN)
Table 35 North America Muscarinic Acetylcholine Receptor Market Outlook, By Nu-0467154 (2021-2030) ($MN)
Table 36 North America Muscarinic Acetylcholine Receptor Market Outlook, By Anauex-273 (2021-2030) ($MN)
Table 37 North America Muscarinic Acetylcholine Receptor Market Outlook, By Other Products (2021-2030) ($MN)
Table 38 North America Muscarinic Acetylcholine Receptor Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 39 North America Muscarinic Acetylcholine Receptor Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 40 North America Muscarinic Acetylcholine Receptor Market Outlook, By Speciality Stores (2021-2030) ($MN)
Table 41 North America Muscarinic Acetylcholine Receptor Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 42 North America Muscarinic Acetylcholine Receptor Market Outlook, By Application (2021-2030) ($MN)
Table 43 North America Muscarinic Acetylcholine Receptor Market Outlook, By Chronic Obstructive Pulmonary Disease (2021-2030) ($MN)
Table 44 North America Muscarinic Acetylcholine Receptor Market Outlook, By Alzeheimers Disease (2021-2030) ($MN)
Table 45 North America Muscarinic Acetylcholine Receptor Market Outlook, By Psychiatric Disorders (2021-2030) ($MN)
Table 46 North America Muscarinic Acetylcholine Receptor Market Outlook, By Attention Deficit Hyperactivity Disorder (2021-2030) ($MN)
Table 47 North America Muscarinic Acetylcholine Receptor Market Outlook, By Memory Impairment (2021-2030) ($MN)
Table 48 North America Muscarinic Acetylcholine Receptor Market Outlook, By End User (2021-2030) ($MN)
Table 49 North America Muscarinic Acetylcholine Receptor Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
Table 50 North America Muscarinic Acetylcholine Receptor Market Outlook, By Healthcare Facilities (2021-2030) ($MN)
Table 51 North America Muscarinic Acetylcholine Receptor Market Outlook, By Research Institutes (2021-2030) ($MN)
Table 52 North America Muscarinic Acetylcholine Receptor Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
Table 53 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Country (2021-2030) ($MN)
Table 54 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Type (2021-2030) ($MN)
Table 55 Europe Muscarinic Acetylcholine Receptor Market Outlook, By M1 (2021-2030) ($MN)
Table 56 Europe Muscarinic Acetylcholine Receptor Market Outlook, By M4 (2021-2030) ($MN)
Table 57 Europe Muscarinic Acetylcholine Receptor Market Outlook, By M5 (2021-2030) ($MN)
Table 58 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Other Types (2021-2030) ($MN)
Table 59 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Product (2021-2030) ($MN)
Table 60 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Tropicamide (2021-2030) ($MN)
Table 61 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Nu-0467154 (2021-2030) ($MN)
Table 62 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Anauex-273 (2021-2030) ($MN)
Table 63 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Other Products (2021-2030) ($MN)
Table 64 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 65 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 66 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Speciality Stores (2021-2030) ($MN)
Table 67 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 68 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Application (2021-2030) ($MN)
Table 69 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Chronic Obstructive Pulmonary Disease (2021-2030) ($MN)
Table 70 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Alzeheimers Disease (2021-2030) ($MN)
Table 71 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Psychiatric Disorders (2021-2030) ($MN)
Table 72 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Attention Deficit Hyperactivity Disorder (2021-2030) ($MN)
Table 73 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Memory Impairment (2021-2030) ($MN)
Table 74 Europe Muscarinic Acetylcholine Receptor Market Outlook, By End User (2021-2030) ($MN)
Table 75 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
Table 76 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Healthcare Facilities (2021-2030) ($MN)
Table 77 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Research Institutes (2021-2030) ($MN)
Table 78 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
Table 79 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Country (2021-2030) ($MN)
Table 80 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Type (2021-2030) ($MN)
Table 81 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By M1 (2021-2030) ($MN)
Table 82 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By M4 (2021-2030) ($MN)
Table 83 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By M5 (2021-2030) ($MN)
Table 84 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Other Types (2021-2030) ($MN)
Table 85 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Product (2021-2030) ($MN)
Table 86 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Tropicamide (2021-2030) ($MN)
Table 87 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Nu-0467154 (2021-2030) ($MN)
Table 88 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Anauex-273 (2021-2030) ($MN)
Table 89 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Other Products (2021-2030) ($MN)
Table 90 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 91 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 92 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Speciality Stores (2021-2030) ($MN)
Table 93 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 94 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Application (2021-2030) ($MN)
Table 95 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Chronic Obstructive Pulmonary Disease (2021-2030) ($MN)
Table 96 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Alzeheimers Disease (2021-2030) ($MN)
Table 97 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Psychiatric Disorders (2021-2030) ($MN)
Table 98 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Attention Deficit Hyperactivity Disorder (2021-2030) ($MN)
Table 99 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Memory Impairment (2021-2030) ($MN)
Table 100 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By End User (2021-2030) ($MN)
Table 101 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
Table 102 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Healthcare Facilities (2021-2030) ($MN)
Table 103 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Research Institutes (2021-2030) ($MN)
Table 104 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
Table 105 South America Muscarinic Acetylcholine Receptor Market Outlook, By Country (2021-2030) ($MN)
Table 106 South America Muscarinic Acetylcholine Receptor Market Outlook, By Type (2021-2030) ($MN)
Table 107 South America Muscarinic Acetylcholine Receptor Market Outlook, By M1 (2021-2030) ($MN)
Table 108 South America Muscarinic Acetylcholine Receptor Market Outlook, By M4 (2021-2030) ($MN)
Table 109 South America Muscarinic Acetylcholine Receptor Market Outlook, By M5 (2021-2030) ($MN)
Table 110 South America Muscarinic Acetylcholine Receptor Market Outlook, By Other Types (2021-2030) ($MN)
Table 111 South America Muscarinic Acetylcholine Receptor Market Outlook, By Product (2021-2030) ($MN)
Table 112 South America Muscarinic Acetylcholine Receptor Market Outlook, By Tropicamide (2021-2030) ($MN)
Table 113 South America Muscarinic Acetylcholine Receptor Market Outlook, By Nu-0467154 (2021-2030) ($MN)
Table 114 South America Muscarinic Acetylcholine Receptor Market Outlook, By Anauex-273 (2021-2030) ($MN)
Table 115 South America Muscarinic Acetylcholine Receptor Market Outlook, By Other Products (2021-2030) ($MN)
Table 116 South America Muscarinic Acetylcholine Receptor Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 117 South America Muscarinic Acetylcholine Receptor Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 118 South America Muscarinic Acetylcholine Receptor Market Outlook, By Speciality Stores (2021-2030) ($MN)
Table 119 South America Muscarinic Acetylcholine Receptor Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 120 South America Muscarinic Acetylcholine Receptor Market Outlook, By Application (2021-2030) ($MN)
Table 121 South America Muscarinic Acetylcholine Receptor Market Outlook, By Chronic Obstructive Pulmonary Disease (2021-2030) ($MN)
Table 122 South America Muscarinic Acetylcholine Receptor Market Outlook, By Alzeheimers Disease (2021-2030) ($MN)
Table 123 South America Muscarinic Acetylcholine Receptor Market Outlook, By Psychiatric Disorders (2021-2030) ($MN)
Table 124 South America Muscarinic Acetylcholine Receptor Market Outlook, By Attention Deficit Hyperactivity Disorder (2021-2030) ($MN)
Table 125 South America Muscarinic Acetylcholine Receptor Market Outlook, By Memory Impairment (2021-2030) ($MN)
Table 126 South America Muscarinic Acetylcholine Receptor Market Outlook, By End User (2021-2030) ($MN)
Table 127 South America Muscarinic Acetylcholine Receptor Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
Table 128 South America Muscarinic Acetylcholine Receptor Market Outlook, By Healthcare Facilities (2021-2030) ($MN)
Table 129 South America Muscarinic Acetylcholine Receptor Market Outlook, By Research Institutes (2021-2030) ($MN)
Table 130 South America Muscarinic Acetylcholine Receptor Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
Table 131 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Country (2021-2030) ($MN)
Table 132 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Type (2021-2030) ($MN)
Table 133 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By M1 (2021-2030) ($MN)
Table 134 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By M4 (2021-2030) ($MN)
Table 135 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By M5 (2021-2030) ($MN)
Table 136 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Other Types (2021-2030) ($MN)
Table 137 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Product (2021-2030) ($MN)
Table 138 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Tropicamide (2021-2030) ($MN)
Table 139 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Nu-0467154 (2021-2030) ($MN)
Table 140 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Anauex-273 (2021-2030) ($MN)
Table 141 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Other Products (2021-2030) ($MN)
Table 142 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 143 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 144 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Speciality Stores (2021-2030) ($MN)
Table 145 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 146 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Application (2021-2030) ($MN)
Table 147 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Chronic Obstructive Pulmonary Disease (2021-2030) ($MN)
Table 148 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Alzeheimers Disease (2021-2030) ($MN)
Table 149 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Psychiatric Disorders (2021-2030) ($MN)
Table 150 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Attention Deficit Hyperactivity Disorder (2021-2030) ($MN)
Table 151 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Memory Impairment (2021-2030) ($MN)
Table 152 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By End User (2021-2030) ($MN)
Table 153 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
Table 154 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Healthcare Facilities (2021-2030) ($MN)
Table 155 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Research Institutes (2021-2030) ($MN)
Table 156 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Diagnostic Centers (2021-2030) ($MN)

Product Code: SMRC24386

According to Stratistics MRC, the Global Muscarinic Acetylcholine Receptor Market is accounted for $1.75 billion in 2023 and is expected to reach $2.79 billion by 2030 growing at a CAGR of 6.9% during the forecast period. Muscarinic acetylcholine receptors are a class of receptors that can inhibit postsynaptic neurons and are involved in the regulation of several peripheral and central activities. They are responsible for regulating the parasympathetic nervous system's physiological consequences. It has both inhibitory and excitatory effects that can block or stimulate the response and is stored in the acetylcholine-producing neurons as cholinergic neurons.

According to the American Heart Association, a US-based nonprofit organization that supports medical research, the number of persons affected by Alzheimer's disease and associated dementias in the United States is expected to rise to 9.3 million by 2060.

Market Dynamics:

Driver:

Increasing prevalence of neurological disorders

Neurological conditions, such as Alzheimer's disease, Parkinson's disease, and schizophrenia, are becoming more widespread due to ageing populations and changing lifestyles. Muscarinic acetylcholine receptors play a crucial role in these disorders, making them attractive targets for drug development. Moreover, the market is growing as a result of a dire need to address the burden of neurological illnesses on healthcare systems and the growing need for innovative therapies. This presents both significant possibilities for pharmaceutical companies and researchers in the field, as well as potential hope for patients.

Restraint:

Side effects and safety concerns

Medications targeting muscarinic acetylcholine receptors can lead to adverse effects such as dry mouth, blurred vision, constipation, dizziness, and cognitive impairment. These side effects can impact patient compliance and quality of life, particularly in elderly populations that may already experience some of these symptoms due to age-related issues. Balancing therapeutic benefits with side effects is challenging, potentially limiting patient adherence. Safety concerns also arise due to the potential impact on cardiovascular and respiratory systems. Thus, they are limiting market expansion.

Opportunity:

Targeted therapies

Targeted therapies can offer more precise treatment options, minimising side effects and enhancing therapeutic outcomes. By tailoring interventions to the individual patient's receptor profile, personalised medicine becomes a reality, potentially revolutionising the treatment of conditions like Alzheimer's disease, schizophrenia, and Parkinson's disease. Furthermore, advancements in drug delivery systems and diagnostic tools can optimise the effectiveness of these therapies. This presents a promising avenue for pharmaceutical companies and researchers to develop innovative, patient-centric solutions and drive growth in the market.

Threat:

Regulatory hurdles

Developing drugs targeting muscarinic receptors requires adherence to rigorous regulatory requirements, including extensive clinical trials and safety assessments. These demands lead to extended timelines, increased costs, and the risk of regulatory setbacks. Delays or rejections can hinder market entry and deter pharmaceutical companies. These obstacles may impede innovation, potentially delaying the availability of new treatments for neurological and psychiatric disorders and impacting the market's growth and competitiveness.

COVID-19 Impact

The COVID-19 pandemic has significantly impacted the muscle acetylcholine receptor market. Clinical trial and medication development have been delayed as a result of supply chain interruptions, limitations imposed on research and development operations, and the reorganisation of healthcare resources. Additionally, patient access to muscarinic receptor-related medicines was impacted by the emphasis on telehealth and the decline in in-person healthcare visits. However, the pandemic also underscored the importance of neurological research and innovation, potentially driving increased interest and investment in this market as healthcare systems adapt to future challenges and opportunities.

The Tropicamide segment is expected to be the largest during the forecast period

The Tropicamide segment is estimated to hold the largest share. Tropicamide is a pharmaceutical medication that belongs to a class of drugs known as anticholinergics or muscarinic antagonists. In ophthalmology, it is mainly employed as a cycloplegic and mydriatic agent. Tropicamide works by paralysing the focusing muscle of the eye and dilatation of the pupil by inhibiting muscarinic acetylcholine receptors in the iris and ciliary muscle. The application of tropicamide in ophthalmology highlights its connection to the larger market, which includes medications and treatments that target these receptors to treat a range of illnesses, including psychological and neurological diseases.

The Psychiatric Disorders segment is expected to have the highest CAGR during the forecast period

The Psychiatric Disorders segment is anticipated to have lucrative growth during the forecast period. Muscarinic acetylcholine receptors are a group of receptors in the central nervous system that play a crucial role in regulating various brain functions. Dysfunction in these receptors is implicated in several psychiatric conditions, including schizophrenia, bipolar disorder, and major depressive disorder. This segment of the market focuses on innovative therapies that can offer more effective and targeted treatments for individuals suffering from psychiatric conditions, representing a promising avenue for medical advancements. Hence, this will propel segment demand.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period due to rising healthcare expenditures and a growing geriatric population. It encompasses pharmaceuticals, research tools, and diagnostics associated with muscarinic acetylcholine receptors, vital components in the nervous system. This market is influenced by factors such as the prevalence of neurological disorders, advancing drug development, and increasing research in neurology. Moreover, major pharmaceutical companies, research institutions, and biotechnology firms in the region engage in the development and commercialization of products related to these receptors. Collaborations between academia and industry are common, and precision medicine approaches and targeted therapies are key trends, reflecting a growing focus on personalised healthcare solutions in the region.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period, due to the presence of a well-established healthcare infrastructure, high research and development investments, and a large patient population. The market size is influenced by factors such as the prevalence of conditions related to these receptors, advancements in drug development, and research in neurology and related fields. Furthermore, pharmaceutical companies develop drugs targeting muscarinic acetylcholine receptors for various medical conditions, including neurological disorders like Alzheimer's disease.

Key players in the market:

Some of the key players in the Muscarinic Acetylcholine Receptor Market include AstraZeneca, Anavex Life Sciences Corp., Sosei Heptares, Karuna Therapeutics, Sumitomo Dainippon Pharma Co., Ltd., NeuroHealing Pharmaceuticals Inc., Heptares Therapeutics Ltd., Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Johnson & Johnson, Boehringer Ingelheim International Gmbh, Eli Lilly and Company, Takeda Pharmaceutical Company Ltd, Merck & Co., Inc, AbbVie Inc., Elsevier B.V., Eurofins DiscoverX Corporation and Novus Biologicals.

Key Developments:

In November 2023, AstraZeneca announces multi-year partnership with NHL and NHLPA Hockey Fights Cancer initiative. Through this multi-year partnership, AstraZeneca, the NHLPA, and the NHL will leverage the Hockey Fights Cancer platform to encourage fans to win at their own G.A.M.E: Gauge risk factors, Arrange a screening, make a donation, Educate loved ones.

In July 2023, AstraZeneca India strengthens partnership with SASTRA University. The collaboration between AstraZeneca and SASTRA University aims to strengthen industry-academia ties and equip students with expertise in various aspects of clinical research.

In June 2023, AstraZeneca has entered into an exciting collaboration, exclusive option and license agreement with Quell Therapeutics to develop multiple engineered T-regulator (Treg) cell therapies that have the potential to be curative in Type 1 Diabetes (T1D) and Inflammatory Bowel Disease (IBD) indications.

Types Covered:

M1
M4
M5
Other Types

Products Covered:

Tropicamide
Nu-0467154
Anauex-273
Other Products

Distribution Channels Covered:

Retail Pharmacies
Speciality Stores
Online Pharmacies

Applications Covered:

Chronic Obstructive Pulmonary Disease
Alzeheimers Disease
Psychiatric Disorders
Attention Deficit Hyperactivity Disorder
Memory Impairment

End Users Covered:

Pharmaceutical Companies
Healthcare Facilities
Research Institutes
Diagnostic Centers

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Muscarinic Acetylcholine Receptor Market, By Type

5.1 Introduction
5.2 M1
5.3 M4
5.4 M5
5.5 Other Types

6 Global Muscarinic Acetylcholine Receptor Market, By Product

6.1 Introduction
6.2 Tropicamide
6.3 Nu-0467154
6.4 Anauex-273
6.5 Other Products

7 Global Muscarinic Acetylcholine Receptor Market, By Distribution Channel

7.1 Introduction
7.2 Retail Pharmacies
7.3 Speciality Stores
7.4 Online Pharmacies

8 Global Muscarinic Acetylcholine Receptor Market, By Application

8.1 Introduction
8.2 Chronic Obstructive Pulmonary Disease
8.3 Alzeheimers Disease
8.4 Psychiatric Disorders
8.5 Attention Deficit Hyperactivity Disorder
8.6 Memory Impairment

9 Global Muscarinic Acetylcholine Receptor Market, By End User

9.1 Introduction
9.2 Pharmaceutical Companies
9.3 Healthcare Facilities
9.4 Research Institutes
9.5 Diagnostic Centers

10 Global Muscarinic Acetylcholine Receptor Market, By Geography

10.1 Introduction
10.2 North America
- 10.2.1 US
- 10.2.2 Canada
- 10.2.3 Mexico
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 Italy
- 10.3.4 France
- 10.3.5 Spain
- 10.3.6 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 New Zealand
- 10.4.6 South Korea
- 10.4.7 Rest of Asia Pacific
10.5 South America
- 10.5.1 Argentina
- 10.5.2 Brazil
- 10.5.3 Chile
- 10.5.4 Rest of South America
10.6 Middle East & Africa
- 10.6.1 Saudi Arabia
- 10.6.2 UAE
- 10.6.3 Qatar
- 10.6.4 South Africa
- 10.6.5 Rest of Middle East & Africa

11 Key Developments

11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies

12 Company Profiling

12.1 AstraZeneca
12.2 Anavex Life Sciences Corp.
12.3 Sosei Heptares.
12.4 Karuna Therapeutics.
12.5 Sumitomo Dainippon Pharma Co., Ltd.
12.6 NeuroHealing Pharmaceuticals Inc.
12.7 Heptares Therapeutics Ltd.
12.8 Pfizer Inc.
12.9 GlaxoSmithKline plc
12.10 Novartis AG
12.11 Johnson & Johnson
12.12 Boehringer Ingelheim International Gmbh
12.13 Eli Lilly and Company
12.14 Takeda Pharmaceutical Company Ltd
12.15 Merck & Co., Inc
12.16 AbbVie Inc.
12.17 Elsevier B.V.
12.18 Eurofins DiscoverX Corporation
12.19 Novus Biologicals

ムスカリン性アセチルコリン受容体の2030年までの世界市場予測： タイプ別、製品別、流通チャネル別、用途別、エンドユーザー別、地域別分析

Muscarinic Acetylcholine Receptor Market Forecasts to 2030 - Global Analysis By Type (M1, M4, M5 and Other Types), Product (Tropicamide, Nu-0467154, Anauex-273 and Other Products), Distribution Channel, Application, End User and By Geography

COVID-19の影響

最大のシェアを占める地域

CAGRが最も高い地域：

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます。

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

第4章 ポーターのファイブフォース分析

第5章 世界のムスカリン性アセチルコリン受容体市場：タイプ別

第6章 世界のムスカリン性アセチルコリン受容体市場：製品別

第7章 世界のムスカリン性アセチルコリン受容体市場：流通チャネル別

第8章 世界のムスカリン性アセチルコリン受容体市場：用途別

第9章 世界のムスカリン性アセチルコリン受容体市場：エンドユーザー別

第10章 世界のムスカリン性アセチルコリン受容体市場：地域別

第11章 主要発展

第12章 企業プロファイル